No Data
No Data
No Data
No Data
No Data
American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)
EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 / American CryoStem Corporation (OTC PINK:CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and
AccesswireMar 4, 2022 06:06 ET
American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial
EATONTOWN, NJ / ACCESSWIRE / December 22, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing
AccesswireDec 22, 2021 01:06 ET
American CryoStem Completes Clinical Protocol Design for Long COVID Study
EATONTOWN, NJ / ACCESSWIRE / November 30, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced
AccesswireNov 30, 2021 06:06 ET
American CryoStem to Study New Standardized Treatment Protocols for Wound Healing
EATONTOWN, NJ / ACCESSWIRE / November 16, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing
AccesswireNov 16, 2021 01:06 ET
No Data
No Data